Oncolytic Virus Therapy Market Share

North American Market Forecast

Oncolytic virus therapy market in North America is predicted to account for the largest share of about 39% by the end of 2037 impelled by the growing clinical activities. This has led to the development of new oncolytic viruses’ modifications to existing viruses in the region for serious diseases including cancer. As a result, the demand for oncolytic virus therapy may increase in the region as new modifications would offer more benefits and more patients become eligible for the treatment.

In terms of the number of clinical trial sites, followed by the United States Canada accounts for more than 3% of all global clinical trials.

European Market Statistics

The Europe oncolytic virus therapy market is estimated to be the second largest, during the forecast timeframe led by the rising approvals of oncolytic virus therapy drugs. This has led to the development of new oncolytic viruses’ modifications to existing viruses in the region for serious diseases including cancer. As a result, the demand for oncolytic virus therapy may increase in the region as new modifications would offer more benefits and more patients become eligible for the treatment.